Hussman Strategic Advisors Inc. Makes New Investment in Emergent BioSolutions Inc. (NYSE:EBS)

Hussman Strategic Advisors Inc. acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 21,000 shares of the biopharmaceutical company’s stock, valued at approximately $201,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Stifel Financial Corp acquired a new stake in Emergent BioSolutions during the third quarter worth approximately $96,000. FORA Capital LLC purchased a new position in shares of Emergent BioSolutions during the third quarter worth approximately $103,000. Hilltop Holdings Inc. grew its position in shares of Emergent BioSolutions by 7.9% during the third quarter. Hilltop Holdings Inc. now owns 171,266 shares of the biopharmaceutical company’s stock worth $1,430,000 after acquiring an additional 12,515 shares during the last quarter. FMR LLC grew its position in shares of Emergent BioSolutions by 12.6% during the third quarter. FMR LLC now owns 129,099 shares of the biopharmaceutical company’s stock worth $1,078,000 after acquiring an additional 14,446 shares during the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Emergent BioSolutions during the third quarter worth approximately $141,000. Institutional investors and hedge funds own 78.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on EBS. Benchmark raised their target price on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, January 21st. Finally, StockNews.com upgraded shares of Emergent BioSolutions from a “hold” rating to a “buy” rating in a research report on Monday.

Emergent BioSolutions Stock Performance

NYSE:EBS opened at $7.85 on Friday. The firm has a market cap of $425.04 million, a price-to-earnings ratio of -1.91 and a beta of 1.62. Emergent BioSolutions Inc. has a 1-year low of $1.66 and a 1-year high of $15.10. The firm’s fifty day moving average price is $9.67 and its 200 day moving average price is $9.09. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.